Project Details

Clinical impact of RSVpreF maternal vaccine in infants of Argentina: An Active Surveillance Study

Julia Dvorkin, MD

Summary

BACKGROUND: Argentina is pioneering the implementation of the RSVpreF vaccine in pregnant women in the world. Data on its real impact on young infants remains unknown. GAP: There is insufficient evidence regarding the impact of the RSVpreF vaccine in reducing severe disease and mortality in young infants. It is imperative to investigate the real-world impact of this vaccine. HYPOTHESIS: Maternal immunization (MI) with the RSVpreF vaccine will lead to significant reduction in RSV-related hospital admissions and mortality in the metropolitan area of Buenos Aires (MABA), Argentina. METHODS: To determine the effect of the MI program against RSV on the rates of all-cause and RSV-specific LRTI hospital and PICU admissions of infants under 12 months of age we will conduct an interrupted time-series analysis from January 2018 to December 2025. To estimate the real-world effectiveness of the RSVpreF maternal vaccine against severe-medically attended, laboratory-confirmed RSV infection we will conduct a nested test-negative case-control study in infants under 6 months of age. RESULTS: Pending. IMPACT: Understanding the real-world impact of RSVpreF MI on severe RSV-related LRTI in young infants is essential for its implementation in other low and middle-income countries. This information will be utilized by public health stakeholders worldwide. Website Link: https://unsam.edu.ar/cimet/